The Office of the Inspector General (OIG) of the Department of Health and Human Services is taking a gander at United Therapeutics and its marketing practices. The drugmaker announced Monday that the government agency subpoenaed “documents regarding…the company’s marketing practices relating” to its drugs Remodulin, Tyvaso and Adcirca. All are used to treat pulmonary arterial hypertension (PAH).
The “About Us” section of the OIG’s website notes that the HHS Office of the Inspector General is the federal government’s largest Office of Inspector General department, and is responsible for sussing out waste, fraud and abuse in HHS programs, which include Medicare and Medicaid, among others.
